Compare FOFO & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FOFO | KTTA |
|---|---|---|
| Founded | 2017 | 2020 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.2M | 18.1M |
| IPO Year | 2025 | 2021 |
| Metric | FOFO | KTTA |
|---|---|---|
| Price | $2.10 | $0.50 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 187.9K | 165.6K |
| Earning Date | 12-04-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 77.07 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $486,559.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.09 | ★ N/A |
| Revenue Growth | N/A | ★ 3130.37 |
| 52 Week Low | $1.70 | $0.28 |
| 52 Week High | $21.82 | $2.06 |
| Indicator | FOFO | KTTA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 43.52 |
| Support Level | N/A | $0.48 |
| Resistance Level | N/A | $0.52 |
| Average True Range (ATR) | 0.00 | 0.03 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 0.00 | 41.84 |
Hang Feng Technology Innovation Co Ltd is committed to providing comprehensive corporate management consulting and asset management services, tailored to address the specific needs of each client. Its goal is to empower its clients to design, implement, and achieve their business and investment objectives. Its business consists of two main business lines: (i) corporate management consulting services and (ii) asset management services. The corporate management consulting services include Management consulting and Regulatory compliance and governance consulting, and the asset management services, including fund subscription and fund management services.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.